Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

BACKGROUND: Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has demonstrated efficacy in treating subependymal giant cell astrocytomas (SEGAs) and other manifestations of tuberous sclerosis complex (TSC). However, long-term use of mTOR inhibitors might be necessary. This analysis explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Franz, David N., Belousova, Elena, Sparagana, Steven, Bebin, E. Martina, Frost, Michael D., Kuperman, Rachel, Witt, Olaf, Kohrman, Michael H., Flamini, J. Robert, Wu, Joyce Y., Curatolo, Paolo, de Vries, Petrus J., Berkowitz, Noah, Niolat, Julie, Jóźwiak, Sergiusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924870/
https://www.ncbi.nlm.nih.gov/pubmed/27351628
http://dx.doi.org/10.1371/journal.pone.0158476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924870/
https://www.ncbi.nlm.nih.gov/pubmed/27351628
http://dx.doi.org/10.1371/journal.pone.0158476

Ejemplares similares